Back to results
US 2023/0408523 A1Published application
Methods of identifying gamma delta t cell-modulating agents
AssigneeShattuck Labs, Inc.
InventorsGeorge FROMM, Suresh DE SILVA, Taylor SCHREIBER
Life of this patent
Estimating the term…
Abstract
The present invention relates to, in part, methods that are useful for cancer treatment, and methods for selecting personalized treatment regimens.
Claims69
A method for identifying a cancer therapy, the method comprising:
- (a) obtaining a biological sample, the sample comprising one or more gamma/delta T cells;
- (b) evaluating the sample for the presence, absence, or level of one or more gamma/delta T-cell receptor (TCR) chains;
- and
- (c) selecting a cancer therapy having an ability to signal at the gamma/delta TCR, the cancer therapy comprising one or more butyrophilin proteins, or a fragment thereof.
1 more element
A method for selecting a patient for a cancer treatment, the method comprising:
- (a) obtaining a biological sample, the sample comprising one or more gamma/delta T cells;
- (b) evaluating the sample for the presence, absence, or level of one or more gamma/delta T-cell receptor (TCR) chains;
- and
- (C) selecting a cancer therapy having an ability to signal at the gamma/delta TCR, the cancer therapy comprising one or more butyrophilin proteins, or a fragment thereof.
1 more element
A method for making an agent for the treatment of a cancer in a cancer patient, comprising
- (a) obtaining the agent for the treatment of a cancer, the obtaining comprising:
- (i) evaluating the biological sample from a cancer patient for the presence, absence, or level of one or more gamma/delta T-cell receptor (TCR) chains;
- and
- (ii) selecting a cancer therapy having an ability to signal at the one or more gamma/delta T-cell receptor (TCR) chains, the cancer therapy comprising one or more butyrophilin proteins, or a fragment thereof;
- (b) formulating the identified agent for administration to a cancer patient.
2 more elements
A method for identifying a cancer therapy for a tumor, the method comprising:
- (a) obtaining a biological sample, the sample comprising one or more gamma/delta T cells;
- (b) evaluating the sample for the presence, absence, or level of one or more butyrophilin proteins;
- and
- (c) selecting a cancer therapy having an ability to signal at a gamma/delta TCR, the cancer therapy comprising the one or more butyrophilin proteins, or a fragment thereof.
1 more element
A method for selecting a patient for a cancer treatment, the method comprising:
- (a) obtaining a biological sample, the sample comprising one or more gamma/delta T cells;
- (b) evaluating the sample for the presence, absence, or level of one or more butyrophilin proteins;
- and
- (c) selecting a cancer therapy having an ability to signal at a gamma/delta TCR, the cancer therapy comprising the one or more butyrophilin proteins, or a fragment thereof.
1 more element
Dependencies are inferred from the claim text.